



JFW

BRINKS
HOFER
GILSON
& LIONE

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the below date:

Date: 7-2-04 Name: Stephaine J. Felicetto, 50,814 Signature:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Solomon Ungashe et al.

Appln. No.: 10/716,183

Examiner: Not yet assigned

Filed: November 18, 2003

Art Unit: 1615

For: BIS-ARYL SULFONAMIDES

Attorney Docket No: 10709/35

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

Attached is/are:

- Transmittal Cover Letter (1p. Filed in Dup.); Information Disclosure Statement (5pp. Filed in Dup.); Form PTO 1449 (3pp.); Copies of 64 Cited References (Ref. Nos. A37-A100)
- Return Receipt Postcard

Fee calculation:

- No additional fee is required.
- Small Entity.
- An extension fee in an amount of \$ _____ for a _____-month extension of time under 37 C.F.R. § 1.136(a).
- A petition or processing fee in an amount of \$ _____ under 37 C.F.R. § 1.17(_____.)
- An additional filing fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Small Entity		Not a Small Entity
Total		Minus			x \$9=			x \$18=
Indep.		Minus			x 43=			x \$86=
First Presentation of Multiple Dep. Claim					+\$145=			+\$290=
					Total	\$	Total	\$


Fee payment:

- A check in the amount of \$ _____ is enclosed.
- Please charge Deposit Account No. 23-1925 in the amount of \$ _____. A copy of this Transmittal is enclosed for this purpose.
- Payment by credit card in the amount of \$ _____ (Form PTO-2038 is attached).
- The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925.

Respectfully submitted,

Date 7-2-04

Stephaine J. Felicetto (Reg. No. 50,814)



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

7-2-04

Date of Deposit

Stephanie J. Felicetto

Name of Applicant, Assignee or
Registered Representative

A handwritten signature in black ink, appearing to read "Stephanie J. Felicetto".

7-2-04

Date of Signature

Our Case No.: 10709/35

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ungashe et al.

Serial No.: 10/716,183

Filing Date: November 18, 2003

For: BIS-ARYL SULFONAMIDES

Examiner: To be assigned

Group Art Unit No.: 1615

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

No.	Date	Name
2,997,368	8/22/61	Barent et al.
4,166,452	9/4/79	Generales, Jr.
4,256,108	3/17/81	Theeuwes
4,265,874	5/5/81	Bonsen et al.
4,954,518	9/4/90	Takano et al.
4,992,091	2/12/91	Vinogradoff et al.
4,997,940	3/5/91	Vinogradoff et al.
5,021,591	6/4/91	Vinogradoff et al.
5,071,468	12/10/91	Astles et al.
5,093,364	3/3/92	Richards et al.
5,155,121	10/13/92	Niewohner
5,163,995	11/17/92	Van Heertum et al.
5,185,348	2/9/93	Niewohner et al.
5,217,521	6/8/93	Durr
5,481,005	1/2/96	Wagnon et al.
5,541,186	7/30/96	Breu et al.
5,571,775	11/5/96	Van Heertum
5,589,478	12/31/96	Yamada et al.
5,780,488	7/14/98	Bergman et al.
5,973,148	10/26/99	Ringer et al.
6,136,971	10/24/00	Harrington et al.
6,200,995	3/13/01	De la Brouse-Elwood
6,297,195	10/2/01	Gesing et al.
6,297,239	10/2/01	deSolms et al.
6,316,450	11/13/01	Bromidge et al.
2002/0009116	1/24/02	Kobayashi et al.
2002/0012680	1/31/02	Patel
2002/0013314 A1	1/31/02	Zhu et al.
2002/0037905	3/28/02	Dahl
2002/0037928	3/28/02	Jaen et al.
2002/0065303 A1	5/30/02	Zhu et al.
2002/0072530 A1	6/13/02	Zhu et al.
2002/0103202	8/1/02	Pinto
6,432,624	8/13/02	Kikuchi et al.
2003/0060460	3/27/03	Ohuchida et al.
2003/0139390	7/24/03	McGee et al.

FOREIGN DOCUMENTS

DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	COUNTRY
EP 556673 B1	2/5/93	Europe
DE 3825041 A1	2/15/90	Germany
GB 884847	12/20/61	Great Britain
GB 1332697	10/3/73	Great Britain
CH 561703	5/15/75	Switzerland
WO 94/20142	9/15/1994	WIPO
WO 95/33462	12/14/95	WIPO
WO 96/08483	3/21/96	WIPO

DOCUMENT NUMBER Number-Kind Code (If known)	DATE	COUNTRY
WO 98/11218	3/19/98	WIPO
WO 98/28270	7/2/98	WIPO
WO 98/50029	11/12/98	WIPO
WO 99/17777	4/15/99	WIPO
WO 99/38845	8/5/99	WIPO
WO 99/42465	8/26/99	WIPO
WO 99/55663	11/4/99	WIPO
WO 00/05214	2/3/00	WIPO
WO 00/62778	10/26/00	WIPO
WO 01/00579 A1	1/4/01	WIPO
WO 01/09097 A1	2/8/01	WIPO
WO 01/17971 A1	3/15/01	WIPO
WO 01/19788 A2	3/22/01	WIPO
WO 01/19798 A2	3/22/01	WIPO
WO 01/32646 A2	5/10/01	WIPO
WO 01/56989 A2	8/9/01	WIPO
WO 01/57003 A1	8/9/01	WIPO
WO 01/57020 A1	8/9/01	WIPO
WO 01/56607 A1	8/9/01	WIPO
WO 01/60319 A2	8/23/01	WIPO
WO 02/00633 A1	1/3/02	WIPO
WO 02/30358 A2	4/18/02	WIPO
WO 02/54867 A1	7/18/02	WIPO
WO 02/55501 A2	7/18/02	WIPO
WO 02/59080 A2	8/1/02	WIPO
WO 03/99773 A1	12/4/03	WIPO

OTHER DOCUMENTS

1. Berman et al., *Immunol. Invest.*, 17, pp. 625-677, 1988.
2. Campbell, et al., *J. Exp. Med.*, 195(1), pp. 135-141, 2002.
3. Dahinden, et al., *J. Exp. Med.*, 179, pp. 751-756, 1994.
4. Dannhardt, et. al., *37 Eur.J.Med.Chem.*, pp. 147-161, 2002.
5. Davidson et al., *J Exp Med.*, 184, pp. 241-251, 1996.
6. Kavanaugh et al., *J. Immunol.*, 146, pp. 4149-4156, 1991.
7. Kontoyiannis et al., *Immunity*, 10, pp. 387-398, 1999.
8. Kosiewicz et al., *J Clin Invest.*, 107(6), pp. 695-702, 2001.
9. Kunkel, et al., *J. Exp. Med.* 192(5), pp. 761-767, 2000.
10. Lothrop et al., *J.Amer.Chem.Coc.*, CODEN:JACSAT, 63, pp. 2564-2567, 1941.
11. Murphy, *Rev. Immun.*, 12, pp. 593-633, 1994.
12. Neote, et al., *Cell*, 72, pp. 415-425, 1993.
13. Panwala, et al., *J Immunol.*, 161, pp. 5733-44, 1998.

14. Papadakis, et al., *J. Immunol.*, 165, pp. 5069-5076, 2000.
15. Powrie et al., *Int Immunol.*, 5(11), pp. 1461-71, 1993.
16. Qiuping Z et al., *Cancer Res.*, 63, pp. 6469-77, 2003.
17. Schaarschmidt; Herzenberg, ChemBer., CODEN:CHBEAM, 53, pp. 1388-1399, 1920.
18. Schall, *Cytokine*, 3, pp. 165-183, 1991.
19. Schall, et al., *Curr. Opin. Immunol.*, 6, pp. 865-873, 1994.
20. SciFinder Search Results (February 19, 2004).
21. SciFinder Search Results (February 20, 2004).
22. Silvestri et al., *Medicinal Chemistry Research*, 11(4), pp. 195-218, 2002.
23. Street et.al., *Journal of Chemical Research, Synopses*, (5), pp. 154-55, 1987.
24. Targan et al., *N Engl J Med.*, 337(15), pp. 1029-35, 1997.
25. Uehara, et al., *J. Immunol.*, 168(6), pp. 2811-2819, 2002.
26. Ullmann; Bleier, Chem.Ber., CODEN:CHBEAM, 35, pp. 4273-4280, 1902.
27. Van Riper, et al., *J. Exp. Med.*, 177, pp. 851-856, 1993.
28. Wurbel, et al., *Blood*, 98(9), pp. 2626-2632, 2001.
29. Youn BS, et al., *Apoptosis*, 7, pp. 271-276, 2002.
30. Zaballos, et al., *J. Immunol.*, 162, pp. 5671-5675, 1999.

The requirement of 37 C.F.R. § 1.98(3)(i) that a concise explanation of the relevance of the documents not in the English language be provided is not necessary in this case, because the relevant material in the non-English language documents listed in this Information Disclosure Statement consists of chemical structures, which need no translation or summary to be understood.


In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

Pursuant to 37 CFR 1.98 (a) (2) (i), effective for applications filed after June 30, 2003, Information Disclosure Statements may be filed without copies of U.S. patents and U.S. published applications. Such documents are therefore not being submitted herewith.

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

Applicant(s) respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,


Stephanie J. Felicetto
Registration No. 50,814
Attorney for Applicant(s)

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200



FORM PTO-1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	SERIAL NO. 10/716,183 FILING DATE November 18, 2003 APPLICANT(S): Solomon Ungashe et al.	CASE NO. 10709/35 GROUP ART UNIT 1615
---	--	--

REFERENCE DESIGNATION **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER Number-Kind Code (if known)	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A1 2,997,368	8/22/61	Barent et al.		
	A2 4,166,452	9/4/79	Generales, Jr.		
	A3 4,256,108	3/17/81	Theeuwes		
	A4 4,265,874	5/5/81	Bonsen et al.		
	A5 4,954,518	9/4/90	Takano et al.		
	A6 4,992,091	2/12/91	Vinogradoff et al.		
	A7 4,997,940	3/5/91	Vinogradoff et al.		
	A8 5,021,591	6/4/91	Vinogradoff et al.		
	A9 5,071,468	12/10/91	Astles et al.		
	A10 5,093,364	3/3/92	Richards et al.		
	A11 5,155,121	10/13/92	Niewohner		
	A12 5,163,995	11/17/92	Van Heertum et al.		
	A13 5,185,348	2/9/93	Niewohner et al.		
	A14 5,217,521	6/8/93	Durr		
	A15 5,481,005	1/2/96	Wagnon et al.		
	A16 5,541,186	7/30/96	Breu et al.		
	A17 5,571,775	11/5/96	Van Heertum		
	A18 5,589,478	12/31/96	Yamada et al.		
	A19 5,780,488	7/14/98	Bergman et al.		
	A20 5,973,148	10/26/99	Ringer et al.		
	A21 6,136,971	10/24/00	Harrington et al.		
	A22 6,200,995	3/13/01	De la Brouse-Elwood		
	A23 6,297,195	10/2/01	Gesing et al.		
	A24 6,297,239	10/2/01	deSolms et al.		
	A25 6,316,450	11/13/01	Bromidge et al.		
	A26 2002/0009116	1/24/02	Kobayashi et al.		
	A27 2002/0012680	1/31/02	Patel		
	A28 2002/0013314 A1	1/31/02	Zhu et al.		
	A29 2002/0037905	3/28/02	Dahl		
	A30 2002/0037928	3/28/02	Jaen et al.		
	A31 2002/0065303 A1	5/30/02	Zhu et al.		
	A32 2002/0072530 A1	6/13/02	Zhu et al.		
	A33 2002/0103202	8/1/02	Pinto		
	A34 6,432,624	8/13/02	Kikuchi et al.		
	A35 2003/0060460	3/27/03	Ohuchida et al.		
	A36 2003/0139390	7/24/03	McGee et al.		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO. 10/716,183	CASE NO. 10709/35
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 18, 2003	GROUP ART UNIT Soloman Ungashe et al.
(use several sheets if necessary)	APPLICANT(S): Error! Reference source not found.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL <i>O IPE</i>	DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES OR NO
	A37 EP 556673 B1	2/5/93	Europe		No
	A38 DE 3825041 A1	2/15/90	Germany		No
<i>JUL 05 2004</i>	A39 GB 884847	12/20/61	Great Britain		
	A40 GB 1332697	10/3/73	Great Britain		
	A41 CH 561703	5/15/75	Switzerland		No
	A42 WO 94/20142	9/15/1994	WIPO		
	A43 WO 95/33462	12/14/95	WIPO		
	A44 WO 96/08483	3/21/96	WIPO		No
	A45 WO 98/11218	3/19/98	WIPO		
	A46 WO 98/28270	7/2/98	WIPO		
	A47 WO 98/50029	11/12/98	WIPO		
	A48 WO 99/17777	4/15/99	WIPO		
	A49 WO 99/38845	8/5/99	WIPO		
	A50 WO 99/42465	8/26/99	WIPO		
	A51 WO 99/55663	11/4/99	WIPO		
	A52 WO 00/05214	2/3/00	WIPO		
	A53 WO 00/62778	10/26/00	WIPO		
	A54 WO 01/00579 A1	1/4/01	WIPO		
	A55 WO 01/09097 A1	2/8/01	WIPO		
	A56 WO 01/17971 A1	3/15/01	WIPO		Abstract only
	A57 WO 01/19788 A2	3/22/01	WIPO		
	A58 WO 01/19798 A2	3/22/01	WIPO		
	A59 WO 01/32646 A2	5/10/01	WIPO		
	A60 WO 01/56989 A2	8/9/01	WIPO		
	A61 WO 01/57003 A1	8/9/01	WIPO		
	A62 WO 01/57020 A1	8/9/01	WIPO		
	A63 WO 01/56607 A1	8/9/01	WIPO		Abstract only
	A64 WO 01/60319 A2	8/23/01	WIPO		
	A65 WO 02/00633 A1	1/3/02	WIPO		
	A66 WO 02/30358 A2	4/18/02	WIPO		
	A67 WO 02/54867 A1	7/18/02	WIPO		
	A68 WO 02/55501 A2	7/18/02	WIPO		
	A69 WO 02/59080 A2	8/1/02	WIPO		
	A70 WO 03/99773 A1	12/4/03	WIPO		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTQ-1449	SERIAL NO. 10/716,183	CASE NO. 10709/35
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 18, 2003	GROUP ART UNIT Soloman Ungashe et al.
(use several sheets if necessary)	APPLICANT(S): Error! Reference source not found.	

EXAMINER INITIAL	OTHER ART – NON PATENT LITERATURE DOCUMENTS (Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.)	
	A	B
A71	Berman et al., <i>Immunol. Invest.</i> , 17, pp. 625-677, 1988.	
A72	Campbell, et al., <i>J. Exp. Med.</i> , 195(1), pp. 135-141, 2002.	
A73	Dahinden, et al., <i>J. Exp. Med.</i> , 179, pp. 751-756, 1994.	
A74	Dannhardt, et. al., 37 <i>Eur.J.Med.Chem.</i> , pp. 147-161, 2002.	
A75	Davidson et al., <i>J Exp Med.</i> , 184, pp. 241-251, 1996.	
A76	Kavanaugh et al., <i>J. Immunol.</i> , 146, pp. 4149-4156, 1991.	
A77	Kontoyannis et al., <i>Immunity</i> , 10, pp. 387-398, 1999.	
A78	Kosiewicz et al., <i>J Clin Invest.</i> , 107(6), pp. 695-702, 2001.	
A79	Kunkel, et al., <i>J. Exp. Med.</i> 192(5), pp. 761-767, 2000.	
A80	Lothrop et al., <i>J.Amer.Chem.Coc.</i> , CODEN:JACSAT, 63, pp. 2564-2567, 1941.	
A81	Murphy, <i>Rev. Immun.</i> , 12, pp. 593-633, 1994.	
A82	Neote, et al., <i>Cell</i> , 72, pp. 415-425, 1993.	
A83	Panwala, et al., <i>J Immunol.</i> , 161, pp. 5733-44, 1998.	
A84	Papadakis, et al., <i>J. Immunol.</i> , 165, pp. 5069-5076, 2000.	
A85	Powrie et al., <i>Int Immunol.</i> , 5(11), pp. 1461-71, 1993.	
A86	Qiuping Z et al., <i>Cancer Res.</i> , 63, pp. 6469-77, 2003.	
A87	Schaarschmidt; Herzenberg, <i>ChemBer.</i> , CODEN:CHBEAM, 53, pp. 1388-1399, 1920.	
A88	Schall, <i>Cytokine</i> , 3, pp. 165-183, 1991.	
A89	Schall, et al., <i>Curr. Opin. Immunol.</i> , 6, pp. 865-873, 1994.	
A90	SciFinder Search Results (February 19, 2004)	
A91	SciFinder Search Results (February 20, 2004)	
A92	Silvestri et al., <i>Medicinal Chemistry Research</i> , 11(4), pp. 195-218, 2002.	
A93	Street et.al., <i>Journal of Chemical Research, Synopses</i> , (5), pp. 154-55, 1987.	
A94	Targan et al., <i>N Engl J Med.</i> , 337(15), pp. 1029-35, 1997.	
A95	Uehara, et al., <i>J. Immunol.</i> , 168(6), pp. 2811-2819, 2002.	
A96	Ullmann; Bleier, <i>Chem.Ber.</i> , CODEN:CHBEAM, 35, pp. 4273-4280, 1902.	
A97	Van Riper, et al., <i>J. Exp. Med.</i> , 177, pp. 851-856, 1993.	
A98	Wurbel, et al., <i>Blood</i> , 98(9), pp. 2626-2632, 2001.	
A99	Youn BS, et al., <i>Apoptosis</i> , 7, pp. 271-276, 2002.	
A100	Zaballos, et al., <i>J. Immunol.</i> , 162, pp. 5671-5675, 1999.	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.